Publications by authors named "L Chaigneau"
Background: Although the benefit of supportive care in the postcancer period is now well demonstrated, its implementation in the patient journey remains challenging. This article describes the development, since 2015 and in routine care, of supportive postcancer care comprising a multidisciplinary rehabilitation programme (MRP) based on exercise for patients with early breast cancer.
Methods: As part of quality control, we reviewed all patient files since the programme was implemented.
Background: Attrition continues to be a major hurdle for addiction treatment. Through the prism of the attachment theory, this phenomenon can be understood as a manifestation of the patient's insecure attachment style, needing a highly-responsive care delivery. We developed an electronic health mobile application, co-designed with patients, aimed at helping healthcare teams respond to their patients' needs, and fostering adherence to care.
View Article and Find Full Text PDFArticle Synopsis
- A study called IMADGIST assessed whether extending adjuvant imatinib treatment for an additional three years (totaling six years) improved disease-free survival in patients with high-risk localized gastrointestinal stromal tumors (GIST) who had already received three years of treatment after surgery.
- Conducted across 14 centers, the trial included 136 patients with varied risks of tumor recurrence, finding that those treated for six years had significantly better disease-free survival compared to those who stopped after three years.
- Although there was no significant difference in overall survival, time to imatinib resistance, or quality of life between the two groups, the results suggest that extending treatment can effectively lower relapse rates with
Article Synopsis
- A phase II trial (OSAD93) tested the effectiveness of combining ifosfamide (IFO) and cisplatin (CDDP) without doxorubicin as a neoadjuvant treatment for adult osteosarcoma, focusing on patients with localized high-grade tumors.
- The study included 60 patients who received four courses of chemotherapy, with the primary goal being a Good Histological Response (GHR) of 10% or fewer residual tumor cells in over 30% of patients, and secondary outcomes of disease-free survival (DFS), overall survival (OS), and toxicity.
- Although the GHR target was not achieved, the study showed promising long-term survival rates (5-year DFS 51.
Context And Aims: Eribulin is used in taxane and anthracycline refractory HER2-negative metastatic breast cancers (MBC). Patients treated in pivotal clinical trials achieved low survival rates, therefore, the identification of prognostic criteria for long progression-free survival (PFS) is still an unmet medical need. In this study, we sought to determine potential prognostic criteria for long-term eribulin response in HER2-negative MBC.
View Article and Find Full Text PDF